Periodontitis is one of the most serious and common diseases that occur in dental practice. This is a pathological process in the surrounding tissues of the tooth, which is characterized by inflammation, progressive destruction of periodontal tissues, which as a result leads to the mobility of the teeth and their premature loss.
Conclusions: The results of the literature data analysis testify the efficacy and safety of non-steroidal anti-inflammatory drugs in patients with generalized periodontitis. Based on the results of the research, it can be concluded that the use of Movixicam® ODT reduces the clinical manifestations of inflammatory processes in patients with generalized periodontitis by blocking COX-2 and the synthesis of inflammatory mediators, slowing the progression of pathological processes. Effectively affects matrix metalloproteinases, which causes destruction of bone tissue, and inhibits resorption of the alveolar process. The use of Movixicam® ODT reduces the development of undesirable side effects compared to other non-steroidal anti-inflammatory agents.